There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Objective: To review drug interaction studies of glucagon-like ... needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i ...

MET-097i was tested in five cohorts of 24 participants (20 active drug, 4 placebo ... ultra-long acting, GLP-1RA. The company plans to launch an additional study to confirm this finding across ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...